New Pieces for the Malaria Liver Stage Puzzle: Where Will They Fit?  by Mota, Maria M. & Rodriguez, Ana
are very possibly TLR11/TgPRF-indepen-
dent IL-12 sources not apparent in serum
or in splenic DC cultures that were em-
ployed in these studies. Indeed, evidence
indicates that T. gondii glycosylphospho-
inositols possess TLR2- and TLR4-ac-
tivating properties (Debierre-Grockiego
et al., 2007). It also seems possible that
MyD88-independent pathways leading
to IL-12 could contribute to resistance in
the absence of TLR11 (Kim et al., 2006).
Finally, why hasn’t the immunostimula-
tory property of T. gondii profilin been
selected against through evolutionary
pressure?Formanypathogen-associated
molecular patterns, the answer seems to
be that the innate immune system favors
recognition of molecules essential for
microbial survival (TLR5 recognition of
bacterial flagellin would be one example
[Smith et al., 2003]). This does not seem
to be the case for TgPRF, since expres-
sion of Plasmodium profilin enables in-
vasion, but not TLR11-dependent IL-12
induction. This raises the possibility that
optimal survival of T. gondii in the mouse
host is promoted by recognition of TgPRF
and subsequent IL-12 induction. In this
scenario, absenceof IL-12 inductionwould
lead to uncontrolled parasite growth,
quickly leading to host and consequently
parasite demise. That would seem to be
at odds with the present study, which
shows no difference in virulence between
TgPRF-positive Toxoplasma and TgPRF-
negative parasites expressing P. falcipa-
rum profilin. However, the strain of Toxo-
plasma engineered in these studies is
a member of the type I class of parasites,
which are known for extremely high viru-
lence in mice (one parasite is sufficient to
kill the host in this species). It will be
most valuable to construct TgPRF knock-
out parasites that express Plasmodium
PRF using T. gondii strains with lower vir-
ulence. This will allow an assessment of
TgPRF IL-12-inducing activity in a situa-
tion where stable long-term infection is
the normal outcome.
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Malaria starts with the infection of the liver by Plasmodium parasites. Although extensive analysis of Plasmo-
dium has revealed the expression patterns of this parasite in every stage of its life cycle, the liver stage re-
mained unexplored. Recently, Tarun et al. have published the first complete transcriptome and proteome
analysis of this intriguing parasite stage, providing a list of potential candidate target genes for antimalarial
vaccines and drugs.Malaria is a devastating disease that kills
more than one million children per year,
mainly in sub-Saharan Africa. Plasmo-
dium spp., the causative agents of ma-
laria, are parasites that are transmitted
by the bite of an infected Anopheles
mosquito. During a blood meal, mosqui-
toes injectPlasmodium sporozoites underthe skin of the host, from where they mi-
grate into the circulation and then into
the liver.
The Plasmodium liver stage begins
upon parasite infection of hepatocytes.
During a period lasting between 2 and
16 days depending on the species, the
parasite replicates and undergoes furtherCell Host & Microbdevelopment, ultimately giving rise to
merozoites. Upon release into the blood,
merozoites infect erythrocytes, causing
the fever and the pathologies associated
with malaria. Notably, the liver stage is
essential for the parasite’s amplification;
as Plasmodium parasites are introduced
into its host as a small number ofe 3, February 2008 ª2008 Elsevier Inc. 63
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Previewssporozoites, the replication in hepato-
cytes ensures the release of high numbers
of merozoites into the blood (Prudencio
et al., 2006) (Figure 1).
Although the liver stage is asymptom-
atic and does not induce pathology in
the host, it has been one of the favorite
targets in the quest for an antimalarial
vaccine because immune responses
against this stage can induce complete
protection against malaria (Nussenzweig
and Long, 1994).
Despite the obvious importance of the
liver stage of Plasmodium development
in the host and its potential as a vaccine
target, our knowledge of this stage of
the parasite is regrettably very limited.
Detailed molecular characterization of ev-
ery other stage of Plasmodium has been
performed in recent years, taking advan-
tage of new developments such as the
sequencing of the complete genome of
several species of Plasmodium as well
as greater availability of genomic and
proteomic tools. However, the liver stage
remained elusive due to the significant
technical difficulties that hamper its study.
Some attempts to identify the mole-
cules expressed by the parasite during
its developmental program inside the he-
patocyte have beenmade in recent years.
In the first study, the authors used axeni-
cally cultured liver stages from the rodent
malaria parasite Plasmodium yoelii, which
enabled them to identify 652 transcripts
(Wang et al., 2004). However, this system
was quite distant from the biology of host-
Plasmodium interactions in vivo. More
recently, whole infected hepatocyte cul-
tures were studied, producing some frag-
mented information. In this study, a set of
88 putative P. yoelii genes was described
as being expressed during the liver stage
(Gruner et al., 2005).
Recently, Tarun et al. (2008) gained a
more comprehensive insight into the gene
and protein expression profiles of the64 Cell Host & Microbe 3, February 2008 ª20Plasmodium liver stage. Using transgenic
P. yoelii expressing green fluorescent pro-
tein (GFP), they were able to isolate in-
fected hepatocytes from the livers of mice
using fluorescence-activated cell sorting
(FACS). This approach finally allowed re-
searchers to isolate sufficient numbers
of infected hepatocytes to perform geno-
mic and proteomic analyses and has
provided the first extensive list of genes
expressed during the liver stage of Plas-
modium during an in vivo infection in the
mouse.
Most of the efforts in antimalarial vac-
cines targeting the liver stage have fo-
cused on the circumsporozoite protein.
In fact, the most advanced candidate ma-
laria vaccine (RTS/S) uses a sequence of
this protein as its immunogen. Sadly, the
protection achieved with this approach
is only partial (Alonso et al., 2005). Recent
work suggests that other antigens ex-
pressed during the liver stage, besides
the circumsporozoite protein, can induce
protection against the disease (Gruner
et al., 2007; Kumar et al., 2006), reinforc-
ing the idea that the search for new anti-
gens to incorporate in future antimalarial
vaccines is well worthwhile.
The results of Tarun et al. provide a fresh
starting point for the search of new vac-
cine targets against the liver stage of
Plasmodium. Further work identifying
immunogenic proteins that can mediate
protection will possibly lead to new, more
efficient vaccines. The expression of each
candidate protein will have to be analyzed
in the human parasite P. falciparum to en-
sure that the findings obtained from the
P. yoeliimodel are applicable to the human
disease. Alternatively, the recent success
in the cultivation of P. falciparum liver
stage in vitro (Sattabongkot et al., 2006)
opens the exciting possibility of tackling
this human parasite directly by using in-
fected hepatocytes as the startingmaterial
for transcriptomic and proteomic analysis.08 Elsevier Inc.The use of genetically attenuated spo-
rozoites as a vaccination strategy has
also been recently proposed. In this ap-
proach, individuals would be immunized
using Plasmodium strains that have been
genetically modified to eliminate genes
required for development during the liver
stage. These abortive infections induce
complete protection in murine malaria
models and are expected to be also highly
effective in humans (Waters et al., 2005).
Consequently, the identification of pro-
teins expressed in the liver stage by Tarun
et al. paves the way to finding novel es-
sential genes required for Plasmodium
liver stage development that could be
eliminated in the attenuated vaccination
strains. Despite the promising science be-
hind these attenuated vaccines, however,
this approach still faces implementation
problems, including the high cost of pro-
duction of a whole sporozoite vaccine.
The new list of molecules expressed in
the liver stage, now reported by Tarun
et al., will also provide valuable tools to
study the biology behind the Plasmodium
developmental program inside the he-
patocyte. This stage represents a major
challenge in the Plasmodium life style.
Indeed, coming from an extracellular life
at variable temperature in the salivary
glands of a mosquito, Plasmodium para-
sites must quickly adapt to an intracellular
life at 37C in the mammalian host. In
addition, in a short period of time, the par-
asite changes from a cell cycle arrest in-
vasive stage to one presenting the most
remarkable replication rate observed in
any eukaryotic system. This leads to the
formation of another invasive, nonrepli-
cating stage of the parasite that eventually
leaves the liver surrounded by a hepato-
cyte membrane (Sturm et al., 2006). All
these dramatic metabolic changes and
specialized cellular processes must be
accompanied by precisely regulated ex-
pression of genes, some of which might
be represented in this list of molecules. It
is most likely that many pieces required
to build the liver stage puzzle are present
in this list. These molecules now need to
be studied in functional assays in order
to determine their exact role in the pro-
cesses taking place in the infected liver.
In summary, besides the potential in
providing new tools for vaccination strate-
gies, Tarun et al. identify a significant
amount of candidate molecules whose
expression can be knocked out or testedFigure 1. Plasmodium Liver Stage Development
Plasmodium sporozoites invade hepatocytes, forming a vacuole, within which they replicate and develop,
forming thousands of merozoites. After complete development, merozoites are released in the blood.
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Previewsin functional assays in order to gain
a more accurate and complete insight
into their role in each process of liver
stage development. The liver stage puzzle
is under construction, and many new
pieces are now becoming available. The
coming years hopefully will show us
where should they be placed.
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